Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium Tc 99m anti-CD4 Fab fragment
- Development stage
- Unknown
- Lead developer
- Universität Leipzig
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Technetium Tc 99m anti-CD4 Fab fragment is a diagnostic radiopharmaceutical composed of a Fab fragment of an anti-CD4 antibody labeled with the radioisotope Technetium-99m (99mTc). The anti-CD4 Fab fragment specifically targets and binds to CD4 antigens, which are predominantly found on the surface of T-helper lymphocytes. This specific binding allows for the visualization and imaging of CD4-positive cells within the body using Single-Photon Emission Computed Tomography (SPECT), as the 99mTc radioisotope emits detectable gamma rays. The use of a Fab fragment, a smaller portion of an antibody, is intended to facilitate faster clearance from the bloodstream and improve image contrast compared to intact antibodies. This agent has been explored in research settings for its potential in diagnostic imaging of inflammatory conditions, such as arthritis, and for detecting the presence of CD4-positive cell infiltrates in various diseases, including certain cancers.
- Brand names
- LeuTect
- Other names
- 99Tcm-anti-CD4 Fab' fragments
02
Targets
CD4 (T lymphocyte surface antigen)
Beyond the preview
Go deeper on technetium Tc 99m anti-CD4 Fab fragment.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium Tc 99m anti-CD4 Fab fragment.